Lantheus Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Lantheus Holdings, Inc.
100.43
−0.42%
vs ±4.6% implied · ×0.09
shaded = implied · ▲▼ = realized
Lantheus has 9 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceOn February 6, 2023, we acquired Cerveau and made an upfront payment of approximately $35.3 million to the Cerveau Stockholders.
LNTH 10-Kaccession 0001193125-26-073498
SentenceThis category of revenues also includes royalties and other milestone payments received from our strategic partners that have commercialized products pursuant to license arrangements with us as well as CDMO revenue generated by Evergreen, which we acquired on April 1, 2025.
LNTH 10-Kaccession 0001193125-26-073498
SentenceJubilant HollisterStier ("JHS") is currently a significant supplier of DEFINITY.
LNTH 10-Kaccession 0001193125-26-073498
SentenceIn November 2025 and in accordance with the terms of the Sale and Purchase Agreement, we finalized the net working capital accounts with Life Medical and we received a $2.3 million payment from Life Medical.
LNTH 10-Kaccession 0001193125-26-073498
SentencePreviously, on July 3, 2024,we acquired from Life Molecular the global rights to RM2, its clinical stage, gastrin-releasing peptide receptor ("GRPR")-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, previously referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 (and which we now refer to as LNTH-2402 and LNTH-2401, respectively), for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition (the "RM2 Asset Purchase"), pursuant to the Sublicense, Development and Collaboration Agreement, by and between us and Life Molecular, dated as of June 27, 2024 (the "RM2 Sublicense Agreement").
LNTH 10-Kaccession 0001193125-26-073498
SentenceOn June 18, 2024, we acquired Meilleur, including its asset NAV-4694, an investigational late-stage F-18-labeled PET imaging agent that targets beta amyloids in Alzheimer's disease.
LNTH 10-Kaccession 0001193125-26-073498
SentenceUnder the terms of the PNT2003 License Agreement, we paid POINT an upfront payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones.
LNTH 10-Kaccession 0001193125-26-073498
SentenceOn June 15, 2024, we entered into an agreement with Radiopharm Theranostics Limited ("Radiopharm") to acquire all of Radiopharm's rights to two licensed preclinical assets for an upfront payment of $2.0 million (the "Radiopharm Asset Purchase").
LNTH 10-Kaccession 0001193125-26-073498
SentenceInternationally, we previously licensed exclusive rights to Curium Pharma ("Curium") to develop and commercialize piflufolastat F-18 in Europe, where it is being commercialized in the European Union under the brand name PYLCLARI.
LNTH 10-Kaccession 0001193125-26-073498
SentenceOn September 24, 2025, we announced an exclusive licensing agreement for GE HealthCare Limited ("GE Healthcare") to develop, manufacture, and commercialize Lantheus' piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use.
LNTH 10-Kaccession 0001193125-26-073498
Expected move
Inputs8Q avg ±11.0%·×0.15·cheap
straddle ±1.8%
spot 100.46exp Nov 20ATM strike 100ATM straddle 2.12IV 11%